MacroGenics, Inc. (MGNX)
After hours:
| Previous Close | 14.6700 |
| Open | 4.5000 |
| Bid | 3.2600 x 100 |
| Ask | 3.3400 x 200 |
| Day's Range | 3.1500 - 4.8800 |
| 52 Week Range | 3.1400 - 21.8800 |
| Volume | |
| Avg. Volume | 2,013,169 |
| Market Cap | 207.075M |
| Beta (5Y Monthly) | 2.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.80 |
- GuruFocus.com
Macrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ...
Insight into Macrogenics' Financial Health and Future Clinical Prospects
Insider MonkeyMacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript
MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript May 10, 2024 MacroGenics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. We will begin the MacroGenics 2024 First Quarter Corporate Progress and Financial Results Conference Call in just […]
GlobeNewswireMacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported finan
